• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性前列腺癌中的成骨细胞功能与骨软化症

Osteoblast function and osteomalacia in metastatic prostate cancer.

作者信息

Clarke N W, McClure J, George N J

机构信息

Department of Urological Surgery, University Hospital South Manchester, UK.

出版信息

Eur Urol. 1993;24(2):286-90. doi: 10.1159/000474311.

DOI:10.1159/000474311
PMID:8375452
Abstract

This study has examined the effect of prostate cancer on bone matrix formation and mineralisation by osteoblasts, with special reference to osteomalacia. Sixty-seven patients with prostatic bone metastases underwent transiliac bone biopsy after double tetracycline labelling. Histomorphometric analysis was then undertaken in areas distant from, local to and infiltrated by prostate cancer. In bone free of tumour (n = 45) and bone surrounding metastases (n = 7) both matrix formation and corrected mineral apposition rate were low. By comparison osteoid surface, osteoid volume and mineral apposition rate were markedly increased within metastases (tumor-free bone vs. metastatic bone, p < 0.0001), a finding consistent with a high bone turnover state. Although osteoblast function was disturbed both within metastases and in tumour-free areas, classical osteomalacia was not associated with prostate cancer.

摘要

本研究检测了前列腺癌对成骨细胞骨基质形成和矿化的影响,并特别提及骨软化症。67例有前列腺骨转移的患者在双四环素标记后接受了髂骨活检。然后在远离前列腺癌、前列腺癌局部及受其浸润的区域进行组织形态计量分析。在无肿瘤的骨组织(n = 45)和转移灶周围的骨组织(n = 7)中,基质形成和校正后的矿物质沉积率均较低。相比之下,转移灶内类骨质表面、类骨质体积和矿物质沉积率显著增加(无肿瘤骨组织与转移骨组织相比,p < 0.0001),这一发现与高骨转换状态一致。尽管转移灶内和无肿瘤区域的成骨细胞功能均受到干扰,但典型的骨软化症与前列腺癌无关。

相似文献

1
Osteoblast function and osteomalacia in metastatic prostate cancer.转移性前列腺癌中的成骨细胞功能与骨软化症
Eur Urol. 1993;24(2):286-90. doi: 10.1159/000474311.
2
Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia.前列腺癌硬化性骨转移的组织形态计量学分析——特别提及骨软化症
Cancer. 1983 Mar 1;51(5):918-24. doi: 10.1002/1097-0142(19830301)51:5<918::aid-cncr2820510526>3.0.co;2-j.
3
Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone.前列腺癌骨转移中局灶性加速骨形成与骨软化的鉴别
Br J Urol. 1993 Jul;72(1):98-103. doi: 10.1111/j.1464-410x.1993.tb06467.x.
4
[Prostatic osteocondensing metastases and osteomalacia. Value of histomorphometric study. Preliminary results].[前列腺骨凝聚性转移与骨软化症。组织形态计量学研究的价值。初步结果]
Presse Med. 1985 Oct 19;14(35):1823-7.
5
Bone mineral density and histology in distal renal tubular acidosis.远端肾小管酸中毒中的骨矿物质密度与组织学
Kidney Int. 2001 Mar;59(3):1086-93. doi: 10.1046/j.1523-1755.2001.0590031086.x.
6
Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature.与转移性前列腺癌相关的致癌性骨软化症:病例报告及文献综述
J Am Geriatr Soc. 1993 Sep;41(9):983-5. doi: 10.1111/j.1532-5415.1993.tb06765.x.
7
[Biological and histological profile of osteomalacia in condensing prostatic osteosis. Apropos of 4 cases].
Rev Rhum Mal Osteoartic. 1982 Feb;49(2):81-5.
8
Morphometric evidence for bone resorption and replacement in prostate cancer.前列腺癌中骨吸收和替代的形态计量学证据。
Br J Urol. 1991 Jul;68(1):74-80. doi: 10.1111/j.1464-410x.1991.tb15260.x.
9
The spectrum of pathology in osteomalacia.骨软化症的病理学范围。
Appl Pathol. 1987;5(3):160-71.
10
[Stimulation of osteoblasts in skeletal metastases--a quantitative study].[骨骼转移中对成骨细胞的刺激——一项定量研究]
Z Orthop Ihre Grenzgeb. 1990 Sep-Oct;128(5):447-52. doi: 10.1055/s-2008-1039594.

引用本文的文献

1
Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance.骨髓脂肪细胞诱导癌症相关成纤维细胞和免疫逃逸,增强侵袭和耐药性。
Cancer Sci. 2023 Jun;114(6):2674-2688. doi: 10.1111/cas.15786. Epub 2023 Mar 28.
2
Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review.骨折风险评估算法对前列腺癌患者骨健康评估及改善的意义:一项综述
Turk J Urol. 2019 Feb 20;45(4):245-253. doi: 10.5152/tud.2019.11736. Print 2019 Jul.
3
Systematic Review of the Outcomes of Surgical Treatment of Prostate Metastases to the Spine.
前列腺脊柱转移瘤外科治疗结果的系统评价
Global Spine J. 2017 Aug;7(5):460-468. doi: 10.1177/2192568217710911. Epub 2017 Jun 1.
4
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?针对转移性去势抵抗性前列腺癌中的 Met 和 VEGFR 轴:“游戏结束”?
Target Oncol. 2016 Aug;11(4):431-46. doi: 10.1007/s11523-015-0412-7.
5
Prostate cancer and bone: the elective affinities.前列腺癌与骨骼:选择性亲和关系。
Biomed Res Int. 2014;2014:167035. doi: 10.1155/2014/167035. Epub 2014 May 28.
6
Optimal bone health management strategies in patients with prostate cancer.前列腺癌患者的最佳骨骼健康管理策略
Indian J Urol. 2013 Apr;29(2):89-99. doi: 10.4103/0970-1591.114024.
7
Targeting bone physiology for the treatment of metastatic prostate cancer.针对骨生理学治疗转移性前列腺癌。
Clin Adv Hematol Oncol. 2013 Mar;11(3):134-43.
8
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.在去势抵抗性前列腺癌中靶向 MET 和血管内皮生长因子受体信号通路。
Cancer J. 2013 Jan-Feb;19(1):90-8. doi: 10.1097/PPO.0b013e318281e280.
9
New and emerging therapies for bone metastases in genitourinary cancers.泌尿系统癌症骨转移的新型和新兴疗法。
Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Epub 2012 Nov 23.
10
Bone-targeted agents: preventing skeletal complications in prostate cancer.骨靶向药物:预防前列腺癌骨骼并发症。
Urol Clin North Am. 2012 Nov;39(4):533-46. doi: 10.1016/j.ucl.2012.07.009. Epub 2012 Sep 4.